New study confirms Asciminib's safety for Hard-to-Treat leukemia
NCT ID NCT06427811
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study looked at the safety and effectiveness of asciminib, a newer drug, in 85 Indian adults with a type of leukemia called Ph+ CML-CP. Participants had either a specific gene mutation or had already tried two or more other treatments. The goal was to confirm that asciminib works well and is safe for these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380009, India
-
Novartis Investigative Site
Ahmedabad, Gujarat, 382428, India
-
Novartis Investigative Site
Bengaluru, Karnataka, 560034, India
-
Novartis Investigative Site
Trivandrum, Kerala, 695 011, India
-
Novartis Investigative Site
Pune, Maharashtra, 422001, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 431005, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500082, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700014, India
-
Novartis Investigative Site
Cuttack, 753007, India
-
Novartis Investigative Site
Guwahati, 781003, India
Conditions
Explore the condition pages connected to this study.